lyophilisation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | Lyophilised solid form |
| Solubility | pH dependent; low near pI | Minimum close to pH 5.4 |
| Storage temperature | -20 C solid; 2-8 C solution | Protect from light |
| Isoelectric point | approx. pH 5.4 | Controls solubility minimum |
| Common analytical method | RP-HPLC with mass detection | Purity and identity checks |
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
This image shows the histology of a thyrotroph tumor. These thyrotroph tumors are referred to as thyrotroph adenomas, and are very rare. They typically present as functional macroadenomas and generally appear in individuals in their 50s. Thyrotroph adenomas are not well understood as they only comprise roughly 1% of all pituitary tumors. These tumors typically result in increased secretion of TSH. Individuals with thyrotroph adenomas typically have hyperthyroidism and diffuse goitre. Diffuse goitre refers to the elongated enlargement of the thyroid gland that results from the increased expression of TSH. In histological staining, the thyrotropic cells appear more elongated and spindle shaped and are regularly accompanied by fibrosis. The World Health Organization (WHO) classifies pituitary tumors based on their transcription factors and hormones, as these factors provide insight into the cell lineage and purpose. Thyrotropic adenomas are identified as having the transcription factors, Pit-1, TEF, and GATA-2, and the hormones, β-TSH and α-subunit. Pit-1, in combination with thyrotroph embryonic factor (TEF), contributes to a cell's differentiation into a thyrotroph and helps stimulate the production of β-TSH. GATA-2 is a transcription factor for cells that belong to the Lhx gene family. The heterodimer formation between the α-subunit and β-TSH is critical to TSH secretion. Disruption of the α-subunit gene results in a lack of TSH secretion, hypertrophy and hyperplasia of thyrotrophs, and decreased quantities of somatotrophs and lactotrophs.
=== Chemical industry === Many chemicals exhibit a specific rotation as a unique property (an intensive property like refractive index or specific gravity) which can be used to distinguish it. Polarimeters can identify unknown samples based on this if other variables such as concentration and length of sample cell length are controlled or at least known. This is used in the chemical industry. By the same token, if the specific rotation of a sample is already known, then the concentration and/or purity of a solution containing it can be calculated. Most automatic polarimeters make this calculation automatically, given input on variables from the user.
=== Vascular supply === Axial flaps are supplied by a named artery and vein. This allows for a larger area to be freed from surrounding and underlying tissue, leaving only a small pedicle containing the vessels. Reverse-flow flaps are a type of axial flap in which the supply artery is cut on one end and blood is supplied by backwards flow from the other direction. Random flaps are simpler and have no named blood supply; they are supplied by the subdermal plexus. Pedicled flaps remain attached to the donor site via a pedicle that contains the blood supply, in contrast to a free flap, where the vessels are cut and anastomosed to another blood supply.
Chromosome 3 open reading frame 62 (C3orf62) is a protein that in humans is encoded by the C3orf62 gene. C3orf62 is a glycine-depleted protein relative to the amount of glycine in proteins in the rest of the genome. C3orf62 has a KKXX-like motif and is predicted to be localized in the nucleus. Expression of C3orf62 remains highest in whole blood.
Sources: en.wikipedia.org
The Rho GTPase activating protein 31 is encoded in humans by the ARHGAP31 gene. It is a Cdc42/Rac1 GTPase regulator. ARHGAP31 encodes a GTPase-activating protein (GAP). A variety of cellular processes are regulated by Rho GTPases which cycle between an inactive form bound to GDP and an active form bound to GTP. This cycling between inactive and active forms is regulated by guanine nucleotide exchange factors and GAPs. The encoded protein is a GAP shown to regulate two GTPases involved in protein trafficking and cell growth. ARHGAP31 mutations result in a loss of available active Cdc42 and consequently disrupt actin cytoskeletal structures, causing syndromic cutis aplasia and limb anomalies. Human ARHGAP31 genome location and ARHGAP31 gene details page in the UCSC Genome Browser. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
== Fission products decay and burnup == One of the common fission products is 135Te, which undergoes beta decay with half-life of 19 seconds to 135I. 135I itself is a weak neutron absorber. It builds up in the reactor at a rate proportional to the rate of fission, which is proportional to the reactor thermal power. 135I undergoes beta decay with half-life of 6.57 hours to 135Xe. The yield of 135Xe for uranium fission is 6.3%; about 95% of 135Xe originates from decay of 135I. 135Xe is the most powerful known neutron absorber, with a cross section for thermal neutrons of 2.6×106 barns, so it acts as a "poison" that can slow or stop the chain reaction after a period of operation. This was discovered in the earliest nuclear reactors built by the Manhattan Project for plutonium production. As a result, the designers made provisions in the design to increase the reactor's reactivity (the number of neutrons per fission that go on to fission other atoms of nuclear fuel). 135Xe reactor poisoning played a major role in the Chernobyl disaster. By neutron capture, 135Xe is transformed ("burned") to 136Xe, which is effectively stable and does not significantly absorb neutrons. The burn rate is proportional to the neutron flux, which is proportional to the reactor power; a reactor running at twice the power has twice the xenon burn rate. The production rate is also proportional to reactor power, but due to the half-life time of 135I, this rate depends on the average power over the past several hours.
In May 2016 by a vote of 12–2, with several members of the committee expressing reservations about Sanofi's plans to offer two pens with different ratios of insulin glargine and lixisenatide - one for people who had never taken insulin before and one for people who had; there was also concern about how to handle dosing when switching people from a single drug regimen to the combination drug. In August 2016 the FDA told Sanofi that it was delaying a final decision for three months, and asked Sanofi for more data on how people used the delivery devices. Patent protection for lixisenatide expired in 2020.
=== Rest of 2008 === On 1 September 2008, Antonio Cassese wrote in The Guardian that none of Russian justifications used for the invasion of Georgia "holds water" and "the 1992 agreement authorises only monitoring of internal tensions, not massive use of military force." On 9 September 2008, scholar Frederick Kagan stated before the hearing of the 110th United States Congress that Abkhaz and South Ossetian separatists were engaged in provocations against Georgia and Russian peacekeepers were illegally aiding them instead of curbing them. Michael McFaul stated, "The initial skirmishes between Ossetian and Georgian forces that first sparked this conflict in early August 2008 should have been contained." He further stated, "Nonetheless, Georgian military action within its borders can in no way be equated with or cited as an excuse for Russia's invasion and then dismemberment of a sovereign country." He went on to say that Russian actions in Georgia "were not a mere defensive reaction to Georgian military actions in South Ossetia."
Electrotherapy is the use of electrical energy as a medical treatment. In medicine, the term electrotherapy can apply to a variety of treatments, including the use of electrical devices such as deep brain stimulators for neurological disease. Electrotherapy is a part of neurotherapy aimed at changing the neuronal activity. The term has also been applied specifically to the use of electric current to speed up wound healing. The use of electromagnetic stimulation (EMS) is also widespread for the treatment of muscular pain. Additionally, the term "electrotherapy" or "electromagnetic therapy" has also been applied to a range of alternative medical devices and treatments.
Sources: en.wikipedia.org
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.
Mass spectrometry, usually electrospray ionisation coupled to liquid chromatography, gives an observed mass for comparison with the theoretical value. Peptide mapping after digestion provides complementary sequence-level confirmation.
Short exposure during weighing and handling is generally tolerated, but prolonged storage above refrigerated conditions raises the risk of deamidation, oxidation, and aggregation. The rate depends on pH, buffer composition, and concentration.
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.